| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2010
|
4.79
|
|
2
|
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
|
Nat Genet
|
2008
|
4.37
|
|
3
|
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
|
Blood
|
2008
|
3.85
|
|
4
|
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
|
Blood
|
2010
|
3.69
|
|
5
|
Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
3.50
|
|
6
|
BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
|
Blood
|
2011
|
2.68
|
|
7
|
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.
|
Nat Genet
|
2010
|
2.45
|
|
8
|
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
|
Blood
|
2009
|
2.22
|
|
9
|
Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.
|
Blood
|
2006
|
2.10
|
|
10
|
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
|
Blood
|
2010
|
2.09
|
|
11
|
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.
|
Blood
|
2010
|
1.86
|
|
12
|
Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
|
Blood
|
2006
|
1.74
|
|
13
|
HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species.
|
Nat Immunol
|
2010
|
1.70
|
|
14
|
MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma.
|
Blood
|
2003
|
1.69
|
|
15
|
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.
|
Clin Lymphoma
|
2004
|
1.51
|
|
16
|
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
|
Blood
|
2005
|
1.51
|
|
17
|
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.
|
Oncogene
|
2003
|
1.49
|
|
18
|
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.
|
PLoS One
|
2009
|
1.48
|
|
19
|
Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.
|
Mol Cancer
|
2006
|
1.48
|
|
20
|
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci.
|
Am J Hum Genet
|
2005
|
1.43
|
|
21
|
Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.
|
Blood
|
2002
|
1.40
|
|
22
|
Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis.
|
Proc Natl Acad Sci U S A
|
2009
|
1.39
|
|
23
|
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.
|
Blood
|
2002
|
1.38
|
|
24
|
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
|
J Clin Oncol
|
2009
|
1.34
|
|
25
|
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.
|
Blood
|
2007
|
1.32
|
|
26
|
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.
|
Oncogene
|
2002
|
1.31
|
|
27
|
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
|
Cancer Res
|
2005
|
1.29
|
|
28
|
Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes.
|
Hum Mol Genet
|
2004
|
1.27
|
|
29
|
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.
|
Blood
|
2012
|
1.26
|
|
30
|
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
|
Cancer Res
|
2006
|
1.22
|
|
31
|
High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma.
|
Blood
|
2002
|
1.22
|
|
32
|
Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.
|
Blood
|
2002
|
1.21
|
|
33
|
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
|
Haematologica
|
2010
|
1.17
|
|
34
|
Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
|
Clin Cancer Res
|
2010
|
1.12
|
|
35
|
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
|
Blood
|
2005
|
1.11
|
|
36
|
t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
|
Blood
|
2007
|
1.10
|
|
37
|
Barriers to effective TRAIL-targeted therapy of malignancy.
|
J Clin Oncol
|
2007
|
1.09
|
|
38
|
Identification of Thr29 as a critical phosphorylation site that activates the human proton channel Hvcn1 in leukocytes.
|
J Biol Chem
|
2009
|
1.07
|
|
39
|
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics.
|
FASEB J
|
2005
|
1.07
|
|
40
|
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.
|
Mol Cell Proteomics
|
2009
|
1.07
|
|
41
|
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.
|
Genes Chromosomes Cancer
|
2014
|
1.06
|
|
42
|
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus.
|
Hum Mol Genet
|
2010
|
1.02
|
|
43
|
pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1.
|
Trends Cell Biol
|
2010
|
1.01
|
|
44
|
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.
|
Br J Haematol
|
2012
|
1.00
|
|
45
|
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.
|
Br J Haematol
|
2013
|
0.99
|
|
46
|
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
|
Br J Haematol
|
2007
|
0.98
|
|
47
|
Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
|
Br J Haematol
|
2011
|
0.96
|
|
48
|
Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci.
|
Int J Cancer
|
2002
|
0.94
|
|
49
|
Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein.
|
Genes Chromosomes Cancer
|
2007
|
0.94
|
|
50
|
CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
|
Leuk Res
|
2010
|
0.93
|
|
51
|
Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma--a phase II trial.
|
Br J Haematol
|
2014
|
0.93
|
|
52
|
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia.
|
Br J Haematol
|
2007
|
0.92
|
|
53
|
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL.
|
Blood
|
2008
|
0.91
|
|
54
|
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
|
Int J Cancer
|
2006
|
0.91
|
|
55
|
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
|
Haematologica
|
2011
|
0.91
|
|
56
|
Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination.
|
J Neuropathol Exp Neurol
|
2006
|
0.90
|
|
57
|
GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma.
|
Br J Haematol
|
2008
|
0.90
|
|
58
|
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
|
Mol Cancer Ther
|
2009
|
0.90
|
|
59
|
BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.
|
Blood
|
2007
|
0.90
|
|
60
|
The CBFA2T3/ACSF3 locus is recurrently involved in IGH chromosomal translocation t(14;16)(q32;q24) in pediatric B-cell lymphoma with germinal center phenotype.
|
Genes Chromosomes Cancer
|
2012
|
0.90
|
|
61
|
Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma.
|
Proc Natl Acad Sci U S A
|
2006
|
0.90
|
|
62
|
Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.
|
Br J Haematol
|
2009
|
0.89
|
|
63
|
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia.
|
Blood
|
2009
|
0.89
|
|
64
|
Efficacy of vemurafenib in hairy-cell leukemia.
|
N Engl J Med
|
2014
|
0.87
|
|
65
|
Primary lymphoma-like lesions of the uterine cervix; sheep in wolves' clothing.
|
Br J Haematol
|
2011
|
0.84
|
|
66
|
Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia.
|
Br J Haematol
|
2013
|
0.84
|
|
67
|
Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies.
|
Blood
|
2010
|
0.84
|
|
68
|
p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia.
|
Blood
|
2009
|
0.84
|
|
69
|
The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
|
Biochem Biophys Res Commun
|
2011
|
0.83
|
|
70
|
TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome.
|
Br J Haematol
|
2011
|
0.83
|
|
71
|
Caspase cleavage of Itch in chronic lymphocytic leukemia cells.
|
Biochem Biophys Res Commun
|
2008
|
0.83
|
|
72
|
t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.
|
Blood
|
2012
|
0.82
|
|
73
|
Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.82
|
|
74
|
Bilateral subdural hygromas following intrathecal methotrexate.
|
Br J Haematol
|
2011
|
0.81
|
|
75
|
Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
|
Br J Haematol
|
2011
|
0.81
|
|
76
|
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma.
|
Haematologica
|
2009
|
0.81
|
|
77
|
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma.
|
Br J Haematol
|
2013
|
0.81
|
|
78
|
Proteomic analysis of B-cell malignancies.
|
J Proteomics
|
2010
|
0.81
|
|
79
|
Cloning of immunoglobulin chromosomal translocations by long-distance inverse polymerase chain reaction.
|
Methods Mol Med
|
2005
|
0.80
|
|
80
|
Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies.
|
Cancer Genet Cytogenet
|
2003
|
0.78
|
|
81
|
Proteomic analysis of cell surface membrane proteins in leukemic cells.
|
Methods Mol Biol
|
2007
|
0.77
|
|
82
|
Prdm6 is essential for cardiovascular development in vivo.
|
PLoS One
|
2013
|
0.76
|
|
83
|
BCL7A protein expression in normal and malignant lymphoid tissues.
|
Br J Haematol
|
2012
|
0.75
|
|
84
|
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.
|
Blood
|
2005
|
0.75
|
|
85
|
Bioweapons of tumor mass destruction?
|
J Clin Oncol
|
2003
|
0.75
|
|
86
|
Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma.
|
Br J Haematol
|
2006
|
0.75
|
|
87
|
Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls.
|
Br J Haematol
|
2013
|
0.75
|
|
88
|
Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation.
|
Leuk Res
|
2010
|
0.75
|
|
89
|
Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma.
|
Leuk Lymphoma
|
2003
|
0.75
|